Drug Trial Radar · NCT07713745
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 18, 2026
Primary completion
Jun 1, 2036
Study completion Dec 31, 2036
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN). The study employs a basket design to assess treatment responses across four tumor types commonly associated with NF2-SWN: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas. A shared natural history observational cohort, receiving routine clinical follow-up without investigational treatment, serves as a common control for all substudies. The adaptive platform enables the dynamic addition or closure of substudies based on interim analyses, thereby optimizing trial efficiency. Eligible patients who meet the master protocol criteria and satisfy substudy-specific safety requirements will be assigned to receive the corresponding intervention. Currently open substudies include: * Substudy A: Selumetinib * Substudy B: Luvometinib plus Serplulimab
Conditions
- Neurofibromatosis Type 2
- Vestibular Schwannoma
- Non-vestibular Schwannoma
- Meningioma
- Ependymoma
- NF2-related Schwannomatosis
- NF2
Interventions
Selumetinib 25mg/m2Drug
Oral twice daily per predetermined dosage per protocol.
LuvometinibDrug
Oral once daily per predetermined dosage per protocol.
SerplulimabDrug
Intravenous infusion per predetermined dosage per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumor-Type-Specific Response Rate in NF2-SWN TumorsTime frame: 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.